证券代码：300685 证券简称：艾德生物 公告编号：2026- 006 厦门艾德生物医药科技股份有限公司 2025 年度业绩快报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 （二）财务状况情况说明 报告期末，公司总资产 234,817.94 万元，较期初增长 13.72%；归属于上市公司股东的 所有者权益 203,638.10 万元，较期初增长 10.48%。公司资产负债结构保持稳定，财务状况 健康、良好。 特别提示： 本公告所载 2025 年度的财务数据仅为初步核算数据，未经会计师事务所审计，与年度报告中 披露的最终数据可能存在差异，请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（%） | | --- | --- | --- | --- | | 营业总收入 | 119,767.04 | 110,894.87 | 8.00% | | 营业利润 | 41,765.74 | 29,297.80 | 42.56% | | 利润总额 | 41,122.61 | 28,988.07 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][8]. Core Insights - The government work report has positioned biotechnology and pharmaceuticals as a new pillar industry, emphasizing the importance of innovation and development in this sector [2][11]. - The pharmaceutical and biotechnology sector has underperformed the overall market recently, with a decline of 2.78% compared to a 1.26% drop in the A-share market [1][21]. - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector is 36.18x, which is at the 78.6th percentile of its historical valuation over the past five years [1][26]. Summary by Sections Government Positioning - The government has upgraded the status of the biotechnology and pharmaceutical industry, highlighting its role in driving new productivity and technological innovation [2][11]. - Key development opportunities during the 14th Five-Year Plan include innovation, elderly care, openness, and strengthening basic healthcare services [13]. Market Performance - The overall A-share market saw a decline of 1.26%, with the biotechnology sector declining by 2.78% [1][21]. - Specific sub-sectors such as medical services and medical devices experienced significant declines, with medical services down 4.71% [1][21]. Valuation Metrics - The TTM price-to-earnings ratios for various sub-sectors are as follows: chemical pharmaceuticals at 43.80x, biological products at 45.58x, medical services at 32.48x, and medical devices at 39.48x [26]. Recommended Stocks - Major companies recommended for investment include: - Mindray Medical (300760.SZ): Strong in R&D and international expansion [30]. - United Imaging Healthcare (688271.SH): Focused on high-performance medical imaging and digital solutions [30]. - WuXi AppTec (603259.SH): A leading open-access drug development service platform [30]. - Aier Eye Hospital (300015.SZ): The largest eye care institution in China [30]. - Yuyue Medical (002223.SZ): A leading provider of medical devices and solutions [31].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5] Core Insights - The government work report has positioned biotechnology and pharmaceuticals as a new pillar industry, emphasizing the importance of innovation and development in this sector [2][11] - The pharmaceutical and biotechnology sector has underperformed the overall market recently, with a decline of 2.78% compared to a 1.26% drop in the A-share market [21] - The current price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology sector is 36.18x, which is at the 78.6th percentile of its historical valuation over the past five years [26] Summary by Sections Government Work Report - The report highlights the establishment of biotechnology and pharmaceuticals as a new pillar industry, with a focus on innovation and the development of new technologies such as artificial intelligence and quantum technology [2][11] - Key development opportunities during the 14th Five-Year Plan include innovation, elderly care, openness, and strengthening basic medical services [13] Market Performance - The overall A-share market saw a decline of 1.26%, with the biotechnology sector declining by 2.78%, indicating weaker performance compared to the broader market [21] - Specific declines were noted in various sub-sectors, including medical services down 4.71% and medical devices down 2.94% [21] Valuation Metrics - The P/E ratios for various sub-sectors are as follows: chemical pharmaceuticals at 43.80x, biological products at 45.58x, medical services at 32.48x, and medical devices at 39.48x [26] Recommended Stocks - Major companies recommended for investment include: - Mindray Medical (迈瑞医疗): A leader in medical devices with strong R&D and international expansion [30] - United Imaging Healthcare (联影医疗): Focused on high-performance medical imaging and digital solutions [30] - WuXi AppTec (药明康德): A comprehensive drug development service platform benefiting from global outsourcing trends [30] - Aier Eye Hospital (爱尔眼科): The largest eye care institution in China, leveraging international technology and management [30]

证券代码：300685 证券简称：艾德生物 公告编号：2026-005 厦门艾德生物医药科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 于2025年11月10日召开2025年第一次临时股东大会，审议通过了《关于以集中竞 价交易方式回购公司股份的议案》。公司使用自有资金和/或自筹资金，以集中 竞价方式回购股份用于注销并减少公司注册资本；回购资金总额为不低于人民币 10,000万元且不超过人民币20,000万元，具体回购资金金额以回购实施完成时实 际回购的金额为准；回购股份的实施期限为自公司股东大会审议通过本次回购方 案之日起12个月内。具体内容详见公司于2025年11月18日刊登在巨潮资讯网的 《回购报告书》。 根据《深圳证券交易所上市公司自律监管指引第 9 号—回购股份》等相关规 定，现将公司回购股份进展的有关情况公告如下： 一、截止上月末的回购进展情况 截止 2026 年 2 月 28 日，公司通过回购专用证券账户以集中竞价交易方式实 施回购股份 ...

Core Viewpoint - The report from Guosen Securities indicates that the medical services and consumer-related sectors have experienced long-term adjustments, resulting in valuations at historical lows. By 2026, improvements in supply structure, increased treatment volumes, and store optimization are expected to lead to a dual recovery in fundamentals and valuations, with AI empowerment providing new momentum for leading companies [1][2]. Group 1: Medical Services and Consumer Sectors - The medical services and consumer-related sectors are currently undervalued and poised for performance recovery, with a focus on specific sub-sectors [2]. - In medical services, improvements in supply structure and consumer environment are anticipated to gradually revive business, with stable customer spending and increased treatment volumes. Leading companies are expected to provide positive earnings guidance for 2026, indicating a potential dual recovery in fundamentals and valuations. AI-related business developments are also expected to drive new growth for leading medical service firms. Key companies to watch include Aier Eye Hospital (300015), Gushengtang, Tongce Medical (600763), and Haijia Medical [2]. - The pharmacy sector has shown significant marginal improvement in performance since Q3 2025, with leading companies improving same-store performance quarterly. Regulatory support from nine ministries emphasizes the long-term development direction of industry concentration and chain rate enhancement, with non-pharmaceutical adjustments and store structure optimization driving short-term performance improvements. Key companies include Yifeng Pharmacy (603939) and Dazhenglin (603233) [2]. Group 2: Home Medical Devices - The growth of home medical device companies is driven by increased product penetration and domestic production rates. Rapid growth is observed in products like Continuous Glucose Monitors (CGM) and sleep apnea machines, with leading domestic brands expanding internationally. Traditional categories like blood pressure monitors are increasingly focusing on the high-end market, with domestic brands steadily increasing market share. The combination of high domestic growth and new overseas markets is expected to contribute to sustained performance growth for home medical device companies. Key companies include Yuyue Medical (002223), Kefu Medical (301087), Sanofi Biological (300298), and Ruimaite (301367) [3]. Group 3: Innovative Drug Development - The collaboration for the international expansion of innovative drugs continues to deepen, with recent significant agreements between Shiyao Group and AstraZeneca, as well as Innovent Biologics and Eli Lilly. These collaborations highlight the growing recognition of China's innovative drug development capabilities by multinational pharmaceutical companies, showcasing the efficiency and cost advantages of Chinese innovative drugs [4]. Group 4: Investment Portfolio for 2026 - The investment portfolio for 2026 includes A-shares such as Mindray Medical (300760), United Imaging Healthcare, WuXi AppTec (603259), New Industry (300832), Meihua Medical (301363), Adebiotech (300685), Zhend Medical (603301), Yaokang Biological, Kingmed Diagnostics (603882), Aier Eye Hospital, Yuyue Medical, Yifeng Pharmacy, and Dazhenglin; H-shares include Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi Biopharma, Gushengtang, and Aikang Medical [5].

证券日报网讯 2月10日，艾德生物发布公告称，公司股东厦门科英投资合伙企业（有限合伙）于2026年 2月3日至2月9日通过集中竞价及大宗交易合计减持4775100股，占总股本1.22%，减持计划已完成，减 持后其持股比例由4.08%降至2.86%。 （文章来源：证券日报） ...

证券代码：300685 证券简称：艾德生物 公告编号：2026-004 厦门艾德生物医药科技股份有限公司 关于特定股东减持计划完成的公告 股东厦门科英投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 厦门艾德生物医药科技股份有限公司（以下简称"艾德生物"或"公司"） 于2026年1月28日披露了《关于特定股东减持计划的预披露公告》（公告编号： 2026-002）。持公司股份15,940,946股的股东厦门科英投资合伙企业（有限合伙） （以下简称"厦门科英"）计划在本减持计划公告之日起三个交易日后的三个月 内以大宗交易和集中竞价的方式减持公司股份，减持数量不超过4,775,100股。 厦门科英出具的《股份减持情况告知函》。 特此公告。 二、股东本次减持前后持股情况 | 股东名称 | 股份性质 | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | --- | --- | --- | | | | 持股数量 | 占总股本比 | 持股数量 | 占总股 ...

证券日报网讯2月2日，艾德生物（300685）发布公告称，截至2026年1月31日，公司通过回购专用证券 账户以集中竞价交易方式实施回购股份696，400股，占公司目前总股本的0.18%，回购股份的最高成交 价为22.16元/股，最低成交价为20.50元/股，支付的总金额为14，990，827.10元(不含交易费用)。 ...

格隆汇2月2日丨艾德生物(300685.SZ)公布，截止2026年1月31日，公司通过回购专用证券账户以集中竞 价交易方式实施回购股份696,400股，占公司目前总股本的0.18%，回购股份的最高成交价为22.16元/ 股，最低成交价为20.50元/股，支付的总金额为14,990,827.10元（不含交易费用）。本次回购符合公司 既定的回购股份方案及相关法律法规的要求。 ...

每经AI快讯，艾德生物2月2日晚间发布公告称，截至2026年1月31日，公司通过回购专用证券账户以集 中竞价交易方式实施回购股份约70万股，占公司目前总股本的0.18%，回购股份的最高成交价为22.16 元/股，最低成交价为20.5元/股，支付的总金额约为1499万元。 每经头条（nbdtoutiao）——曾卖劳斯莱斯、保时捷等豪车，汽车销售巨头宝利德如今破产清算：杭州 总部已人去楼空，义乌子公司贴上了封条 （记者 王晓波） ...